InterfacePrescribing & NewTherapies Subgroup

GMMMG Greater Manchester Medicines Management Group

NHS

21st June 2011

Adalimumab solution for injection (Humira®▼)

The New Therapies Subgroup discussed the above drug at a meeting on the 25th March 2008 and June 2011. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered adalimumab for its licensed indication in the management of Crohn's disease.

The group recommends adalimumab as a treatment option for severe active Crohn's disease, defined as a Crohn's Disease Activity Index score ≥ 300 as per NICE TA 187.

Adalimumab may offer practical and financial advantages compared to alternative biological therapies for Crohn's disease.
The group noted the lack of clinical evidence relating to the use of tumour necrosis factor alpha (TNFa) inhibitors subsequent to prior treatment with an alternative TNFa inhibitor. The group recommends that prescribing and monitoring remains within specialist care.

Review Date: June 2013

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.
▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.